Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 1,935 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $190.83, for a total value of $369,256.05. Following the completion of the transaction, the chief marketing officer now owns 326,247 shares of the company’s stock, valued at approximately $62,257,715.01. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Jane Huang also recently made the following trade(s):
- On Friday, June 26th, Jane Huang sold 2,079 shares of Beigene stock. The shares were sold at an average price of $200.29, for a total transaction of $416,402.91.
- On Monday, June 8th, Jane Huang sold 631 shares of Beigene stock. The stock was sold at an average price of $170.84, for a total transaction of $107,800.04.
- On Friday, May 29th, Jane Huang sold 1,500 shares of Beigene stock. The shares were sold at an average price of $163.86, for a total transaction of $245,790.00.
- On Wednesday, April 29th, Jane Huang sold 1,500 shares of Beigene stock. The stock was sold at an average price of $162.30, for a total transaction of $243,450.00.
- On Thursday, April 16th, Jane Huang sold 1,500 shares of Beigene stock. The shares were sold at an average price of $160.00, for a total transaction of $240,000.00.
Beigene stock opened at $188.40 on Wednesday. The company has a quick ratio of 7.89, a current ratio of 7.96 and a debt-to-equity ratio of 0.08. Beigene Ltd has a 12 month low of $114.41 and a 12 month high of $210.35. The company has a fifty day moving average price of $171.15 and a two-hundred day moving average price of $160.73.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Monday, May 11th. The company reported ($4.70) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($4.85) by $0.15. Beigene had a negative net margin of 284.45% and a negative return on equity of 68.64%. The company had revenue of $52.06 million for the quarter, compared to the consensus estimate of $27.00 million. As a group, sell-side analysts expect that Beigene Ltd will post -19.99 EPS for the current year.
A number of brokerages have recently issued reports on BGNE. Morgan Stanley lifted their target price on Beigene from $184.00 to $190.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Maxim Group dropped their price objective on Beigene from $210.00 to $190.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. ValuEngine raised Beigene from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd. Cowen reissued a “buy” rating and set a $200.00 price target on shares of Beigene in a research report on Tuesday, March 3rd. Finally, Zacks Investment Research upgraded shares of Beigene from a “hold” rating to a “buy” rating and set a $182.00 price target for the company in a research note on Friday, May 29th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Beigene presently has a consensus rating of “Buy” and an average price target of $200.73.
Hedge funds have recently modified their holdings of the business. Capital International Investors grew its holdings in shares of Beigene by 25.4% during the first quarter. Capital International Investors now owns 5,706,609 shares of the company’s stock valued at $702,544,000 after purchasing an additional 1,155,679 shares during the last quarter. Primecap Management Co. CA lifted its holdings in shares of Beigene by 70.2% in the 1st quarter. Primecap Management Co. CA now owns 1,700,021 shares of the company’s stock worth $209,290,000 after purchasing an additional 701,444 shares during the last quarter. Norges Bank acquired a new position in Beigene during the 4th quarter valued at approximately $67,449,000. Sands Capital Management LLC grew its stake in Beigene by 102.7% during the 1st quarter. Sands Capital Management LLC now owns 338,366 shares of the company’s stock worth $41,656,000 after buying an additional 171,443 shares during the last quarter. Finally, Pictet Asset Management Ltd. grew its stake in Beigene by 58.0% during the 4th quarter. Pictet Asset Management Ltd. now owns 268,234 shares of the company’s stock worth $3,443,000 after buying an additional 98,452 shares during the last quarter. Institutional investors own 63.78% of the company’s stock.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Read More: Convertible Shares
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.